Drugs / YISAIPU
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03589833 | May 2019 → Mar 2022 | rheumatoid arthritis | Peking Union Medical College Hospital | Completed | Met primary |
| Phase 4 | NCT03411798 | Dec 2017 → Jul 2019 | ankylosing spondylitis | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YISAIPU | “YISAIPU is a recombinant human tumor necrosis factor receptor fusion protein, and tripterygium wilfordii is a chloroform/methanol extract of Tripterygium wilfordii Hook F.” NCT03589833 ↗ |
| Action | Inhibit | “TNF inhibitor” PMID 37657525 ↗ Aug 2023 |
| Modality | Protein / enzyme biologic | “Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein” NCT03589833 ↗ |
| Route | Subcutaneous | “was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.” NCT03589833 ↗ |